Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Dapsone-induced methemoglobinemia: a dose-related occurrence?
Esbenshade AJ, Ho RH, Shintani A, Zhao Z, Smith LA, Friedman DL.
Cancer. 2011 Aug 1;117(15):3485-92. doi: 10.1002/cncr.25904. Epub 2011 Jan 18.
Related citations
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, Coon SK, Bailey C, Barlogie B.
Cancer. 2012 Jan 15;118(2):549-57. doi: 10.1002/cncr.26302. Epub 2011 Jun 30.
The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.
Cantrell LA, Westin SN, Van Le L.
Cancer. 2011 Mar 15;117(6):1220-6. doi: 10.1002/cncr.25590. Epub 2010 Nov 8.
Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study.
Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH.
Cancer. 2011 Aug 15;117(16):3641-9. doi: 10.1002/cncr.25972. Epub 2011 Feb 24.
Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia.
Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA.
Cancer. 2011 Jul 15;117(14):3268-75. doi: 10.1002/cncr.25865. Epub 2011 Jan 24.
Error occurred: cannot get document summary
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J.
Cancer. 2011 Mar 1;117(5):982-91. doi: 10.1002/cncr.25533. Epub 2010 Oct 19.
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.
Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM; CLL Research Consortium.
Cancer. 2011 Jan 1;117(1):116-24. doi: 10.1002/cncr.25379. Epub 2010 Aug 30.
Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
Klarenbach S, Manns B, Reiman T, Reaume MN, Lee H, Lloyd A, Wiebe N, Hemmelgarn B, Tonelli M.
Cancer. 2010 Jul 1;116(13):3224-32.
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN Jr, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS.
Cancer. 2010 May 15;116(10):2409-15.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on